SAN FRANCISCO - CMEA Ventures, a venture capital firm focusing on information technology and life sciences companies, announced that William A. Haseltine, Ph.D. will join its firm as Senior Life Sciences Advisor. Dr. Haseltine is well known as Chairman of the Board of Directors and Chief Executive Officer of Human Genome Sciences. Dr. Haseltine also has more than 20 years of active business focus. He was Founder of seven biotechnology companies, including Dendreon, Diversa, and Human Genome Sciences. Dr. Haseltine was also an advisor to Venture Capital Fund Healthcare Ventures, when he participated in the creation of more than 20 other biotech firms, including Medimmune.
Tom Baruch, Managing General Partner of CMEA Ventures, said, “We are delighted to be working with Dr. Haseltine. He brings a unique perspective based on his scientific accomplishments and his experience as a successful innovator, entrepreneur, and manager. At CMEA, we value creative thinking as a precursor to the ‘change the world’ companies that advance new technologies in which we invest. Dr. Haseltine is just the right addition to continue CMEA’s forward thinking.”
Dr. Haseltine received his doctorate from Harvard University in biophysics and was a professor at Harvard Medical School and Harvard School of Public Health from 1976-1993. He has a distinctive record of academic achievement in both cancer and AIDS research, for which he has received numerous awards and honors. Dr. Haseltine has also published more than 250 scientific papers and authored several books. He founded The Journal of AIDS Research and Retrovirology, and The Journal of Regenerative Medicine.
Additionally, Dr. Haseltine is active in Scientific and Medical Organizations: He is Trustee and Director of The Alliance for Aging Research (AFAR); is on the Board of Trustees of the National Health Museum; Co-Chair of the President’s Council of Cold Spring Harbor Laboratories; serves on the CEO Council of the New York Academy of Sciences; is a member of the Global Business Council on HIV/AIDS Corporate Advisory Board; and is a member of the Board of Visitors of Johns Hopkins Medical School.
Dr. Haseltine is also involved in Public and International Policy. He is a member of the Board of Directors of the U.S. Chamber of Commerce, the Executive Committee of the Brookings Institution, and the Chairman’s Circle of the Asia Society. Dr. Haseltine also serves on the boards of the Aspen Institute of Italy, the Business Executives for National Security, and is a member of The Council of Foreign Relations, as well as the Trilateral Commission.
CMEA Ventures invests in both early and late stage companies, and actively partners with its extended network of corporations, VC firms, institutional investors, strategic partners, and entrepreneurs. CMEA Ventures manages 6 funds and has $771 million of capital. The firm has been an early stage investor in leading Silicon Valley companies such as Flextronics (FLEX), Maxygen (MAXY), Silicon Spice (BRCM), Syrrx (recently purchased by Takeda), Symyx (SMMX), and Virologic (VLGC.) The current CMEA portfolio includes Alexza, Alien Technology, Altus, Ambrx, Bayhill Therapeutics, Biomimetic, Codexis, Entropic, Intermolecular, Perlegen, and Predix, among others.
http://www.cmeaventures.com
Media contact - Meryl Schreibstein 415.352.1520 x260
